|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
|
DK3153526T3
(da)
|
2008-01-31 |
2020-12-14 |
Inst Nat Sante Rech Med |
Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
|
|
US8962803B2
(en)
*
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
CN102203132A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂的组合物和使用方法
|
|
CN102656190A
(zh)
*
|
2009-12-08 |
2012-09-05 |
雅培股份有限两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
|
CN102675460B
(zh)
*
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
|
KR101970025B1
(ko)
*
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
NZ714482A
(en)
|
2012-01-27 |
2017-08-25 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
WO2013181452A1
(en)
|
2012-05-31 |
2013-12-05 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
CA2890346A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
CN104968364A
(zh)
|
2012-12-03 |
2015-10-07 |
百时美施贵宝公司 |
强化免疫调变性Fc融合蛋白的抗癌活性
|
|
MX2015007446A
(es)
|
2012-12-12 |
2015-12-07 |
Vasculox Inc |
Anticuerpos terapeuticos para cd47.
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
CN105209456B
(zh)
|
2013-03-06 |
2018-05-08 |
阿斯利康(瑞典)有限公司 |
表皮生长因子受体的活化突变形式的喹唑啉抑制剂
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
KR20160004299A
(ko)
|
2013-04-09 |
2016-01-12 |
릭스트 바이오테크놀로지, 인코포레이티드 |
옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
|
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
KR102457731B1
(ko)
|
2013-08-08 |
2022-10-21 |
싸이튠 파마 |
병용 약학 조성물
|
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
|
US9580504B1
(en)
*
|
2013-11-07 |
2017-02-28 |
Curetech Ltd. |
Pidilizumab monoclonal antibody therapy following stem cell transplantation
|
|
CN105899232A
(zh)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
用于增强免疫应答的mTOR抑制剂
|
|
US20150140125A1
(en)
*
|
2013-11-19 |
2015-05-21 |
Life Plus, LLC |
Synergistic cancer therapy drug combinations
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
WO2015095404A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
EP3119424A4
(en)
|
2014-03-19 |
2017-09-13 |
MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital |
Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
|
|
AP2016009374A0
(en)
|
2014-03-24 |
2016-08-31 |
Novartis Ag |
Monobactam organic compounds for the treatment of bacterial infections
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
EP3126394B1
(en)
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
US10407737B2
(en)
|
2014-04-10 |
2019-09-10 |
Bio-Marcare Technologies Ltd. |
Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CA2954476C
(en)
|
2014-07-10 |
2023-09-19 |
Novartis Ag |
Immune-stimulating monoclonal antibodies against human interleukin-2
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
WO2016020836A1
(en)
|
2014-08-06 |
2016-02-11 |
Novartis Ag |
Quinolone derivatives as antibacterials
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
SMT202000562T1
(it)
|
2014-09-16 |
2020-11-10 |
Innate Pharma |
Neutralizzazionne delle vie inibitorie nei linfociti
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
WO2016131950A1
(en)
|
2015-02-20 |
2016-08-25 |
Innate Pharma |
Cd73 blockade
|
|
IL250579B2
(en)
|
2014-10-10 |
2023-05-01 |
Innate Pharma |
blocking cd73
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
EP4098278A1
(en)
|
2014-11-13 |
2022-12-07 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
|
WO2016075670A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
|
SI3227339T1
(sl)
|
2014-12-05 |
2022-02-28 |
Memorial Sloan-Kettering Cancer Center |
Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
|
|
EP3227324A4
(en)
|
2014-12-05 |
2018-08-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
|
HRP20192009T1
(hr)
|
2014-12-16 |
2020-02-07 |
Novartis Ag |
Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
AR103726A1
(es)
*
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
|
HK1248603A1
(zh)
|
2015-03-10 |
2018-10-19 |
Aduro Biotech, Inc. |
用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
|
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107667173A
(zh)
|
2015-05-06 |
2018-02-06 |
斯尼普技术有限公司 |
改变微生物种群和改善微生物群
|
|
RS61152B2
(sr)
|
2015-05-12 |
2024-06-28 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
|
EA201792573A1
(ru)
|
2015-05-21 |
2018-04-30 |
Харпун Терапьютикс, Инк. |
Триспецифические связанные белки и способы их применения
|
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
癌のための治療方法及び診断方法
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
JP2018523652A
(ja)
|
2015-07-29 |
2018-08-23 |
ノバルティス アーゲー |
Ｐｄ−１アンタゴニストとｅｇｆｒ阻害剤の組み合わせ物
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
AU2016300208B2
(en)
|
2015-07-29 |
2019-08-08 |
Novartis Ag |
Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
EP4585268A3
(en)
|
2015-09-14 |
2025-10-15 |
Twelve Therapeutics, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
BR112018005322A2
(pt)
|
2015-09-18 |
2018-12-11 |
Arch Oncology, Inc. |
anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
|
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
|
NZ739090A
(en)
|
2015-10-02 |
2025-06-27 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
EP3370733B1
(en)
|
2015-11-02 |
2021-07-14 |
Board of Regents, The University of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
|
CN121154828A
(zh)
|
2015-11-19 |
2025-12-19 |
豪夫迈·罗氏有限公司 |
使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
EP3389711A1
(en)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
RU2625598C2
(ru)
*
|
2015-12-31 |
2017-07-17 |
Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации |
Способ лечения больных локальным раком простаты, относящихся к группе высокого риска прогрессирования заболевания
|
|
JP6949030B2
(ja)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
CN116003593A
(zh)
|
2016-01-11 |
2023-04-25 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
|
CA3012055A1
(en)
|
2016-01-21 |
2017-07-27 |
Innate Pharma |
Neutralization of inhibitory pathways in lymphocytes
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
US11001631B2
(en)
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
US20200270265A1
(en)
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
CA3015913A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
WO2017153433A1
(en)
|
2016-03-08 |
2017-09-14 |
Innate Pharma |
Siglec neutralizing antibodies
|
|
CN116196412A
(zh)
|
2016-03-15 |
2023-06-02 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
JP2019512271A
(ja)
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
|
|
US9988416B2
(en)
|
2016-03-24 |
2018-06-05 |
Novartis Ag |
Alkynyl nucleoside analogs as inhibitors of human rhinovirus
|
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
WO2017167921A1
(en)
|
2016-03-30 |
2017-10-05 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
EP3225253A1
(en)
|
2016-04-01 |
2017-10-04 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
|
|
JP7038353B2
(ja)
|
2016-04-13 |
2022-03-18 |
ヴィヴィア バイオテック，エス．エル |
エクスビボのｂｉｔｅ活性化ｔ細胞
|
|
KR102466763B1
(ko)
|
2016-04-13 |
2022-11-11 |
오리맵스 리미티드 |
항- psma 항체 및 이의 용도
|
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
US11034767B2
(en)
*
|
2016-04-15 |
2021-06-15 |
Trustees Of Dartmouth College |
High affinity B7-H6 antibodies and antibody fragments
|
|
DK3449017T3
(da)
|
2016-04-29 |
2022-03-14 |
Univ Texas |
Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
EP3464286B1
(en)
|
2016-05-24 |
2021-08-18 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
MA45122A
(fr)
|
2016-05-24 |
2019-04-10 |
Constellation Pharmaceuticals Inc |
Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
SG11201810656WA
(en)
|
2016-06-14 |
2018-12-28 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
RU2754507C2
(ru)
|
2016-06-24 |
2021-09-02 |
Инфинити Фармасьютикалз, Инк. |
Комбинированная терапия
|
|
IL299099B2
(en)
|
2016-06-27 |
2025-07-01 |
Univ California |
Cancer treatment combinations
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
US20210369746A1
(en)
|
2016-08-01 |
2021-12-02 |
Molecular Templates, Inc. |
Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
AU2017311585A1
(en)
|
2016-08-12 |
2019-02-28 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
WO2018049014A1
(en)
|
2016-09-07 |
2018-03-15 |
Trustees Of Tufts College |
Dash inhibitors, and uses related thereto
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
CN110191720A
(zh)
|
2016-09-09 |
2019-08-30 |
Tg治疗有限公司 |
用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
|
CA3037518A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
CN109906232B
(zh)
|
2016-09-23 |
2023-11-07 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
|
JP7542946B2
(ja)
|
2016-09-27 |
2024-09-02 |
ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
|
AU2017335839A1
(en)
|
2016-09-29 |
2019-04-18 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
|
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
CN110072540B
(zh)
|
2016-10-12 |
2023-06-02 |
得克萨斯州大学系统董事会 |
用于tusc2免疫治疗的方法和组合物
|
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
WO2018083087A2
(en)
|
2016-11-02 |
2018-05-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Binding proteins
|
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
EP3538112B1
(en)
|
2016-11-09 |
2026-02-25 |
Musc Foundation for Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
MA46852A
(fr)
|
2016-11-17 |
2019-09-25 |
Univ Texas |
Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
EP4324477A3
(en)
|
2016-12-08 |
2024-05-22 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
AU2017375946A1
(en)
|
2016-12-12 |
2019-06-20 |
Genentech, Inc. |
Methods of treating cancer using anti-PD-l1 antibodies and antiandrogens
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
WO2018127570A1
(en)
|
2017-01-05 |
2018-07-12 |
Netris Pharma |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
|
CN110198954A
(zh)
|
2017-01-13 |
2019-09-03 |
艾吉纳斯公司 |
与ny-eso-1结合的t细胞受体和其使用方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
|
CN110573172A
(zh)
|
2017-02-06 |
2019-12-13 |
奥里尼斯生物科学有限公司 |
靶向的工程化干扰素及其用途
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
AU2018223349A1
(en)
|
2017-02-27 |
2019-08-29 |
Bristol-Myers Squibb |
Dosing schedule for a combination of ceritinib and an anti-PD-1 antibody molecule
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
CN110382544B
(zh)
|
2017-03-16 |
2023-12-22 |
先天制药公司 |
用于治疗癌症的组合物和方法
|
|
SG11201908602UA
(en)
*
|
2017-03-22 |
2019-10-30 |
Arch Oncology Inc |
Combination therapy for the treatment of solid and hematological cancers
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
AU2018241944A1
(en)
|
2017-03-31 |
2019-08-15 |
Boehringer Ingelheim International Gmbh |
Anticancer combination therapy
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
EP4368200A3
(en)
|
2017-04-05 |
2024-07-17 |
Boehringer Ingelheim International GmbH |
Anticancer combination therapy
|
|
TWI690538B
(zh)
|
2017-04-05 |
2020-04-11 |
瑞士商赫孚孟拉羅股份公司 |
特異性結合至pd1至lag3的雙特異性抗體
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
KR20200005540A
(ko)
|
2017-04-14 |
2020-01-15 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
|
US12134654B2
(en)
|
2017-04-19 |
2024-11-05 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CA3059769A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
AR111658A1
(es)
|
2017-05-05 |
2019-08-07 |
Novartis Ag |
2-quinolinonas tricíclicas como agentes antibacteriales
|
|
AU2018265856B2
(en)
|
2017-05-12 |
2023-04-27 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
US12215151B2
(en)
|
2017-05-31 |
2025-02-04 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
|
KR20200041834A
(ko)
|
2017-06-01 |
2020-04-22 |
젠코어 인코포레이티드 |
Cd123 및 cd3에 결합하는 이중특이성 항체
|
|
MX2019014199A
(es)
|
2017-06-02 |
2020-01-23 |
Boehringer Ingelheim Int |
Tratamiento de combinacion antineoplasico.
|
|
AU2018275894B2
(en)
|
2017-06-02 |
2025-04-24 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
AU2018298676A1
(en)
|
2017-07-10 |
2019-12-19 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
|
KR102922386B1
(ko)
|
2017-07-21 |
2026-02-04 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
|
US20200239559A1
(en)
|
2017-09-29 |
2020-07-30 |
Boehringer Ingelheim International Gmbh |
Anti igf, anti pd-1, anti-cancer combination therapy
|
|
WO2019068907A1
(en)
|
2017-10-06 |
2019-04-11 |
Innate Pharma |
RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
|
|
CN119930795A
(zh)
|
2017-10-12 |
2025-05-06 |
得克萨斯大学体系董事会 |
用于免疫疗法的t细胞受体
|
|
HRP20241268T1
(hr)
|
2017-10-13 |
2024-12-06 |
Harpoon Therapeutics, Inc. |
Trispecifični proteini i postupci primjene
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
US20210189336A1
(en)
|
2017-10-18 |
2021-06-24 |
Vivia Biotech, S.L. |
Bite-activated car-t cells
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
KR20200085780A
(ko)
|
2017-11-07 |
2020-07-15 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
암의 치료에서 car-t 또는 car-nk 세포를 사용한 lilrb4 표적화
|
|
KR20200088386A
(ko)
|
2017-11-14 |
2020-07-22 |
화이자 인코포레이티드 |
Ezh2 억제제 병용 요법
|
|
EP3710455A1
(en)
|
2017-11-17 |
2020-09-23 |
Novartis AG |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
JP7194481B2
(ja)
|
2017-11-17 |
2022-12-22 |
メルク・シャープ・アンド・ドーム・エルエルシー |
免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
|
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
CA3084821A1
(en)
|
2017-12-15 |
2019-06-20 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer using exosomes-associated gene editing
|
|
JP2021507906A
(ja)
|
2017-12-20 |
2021-02-25 |
ノバルティス アーゲー |
抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
US20200354424A1
(en)
|
2018-01-26 |
2020-11-12 |
Orionis Biosciences, Inc. |
Xcr1 binding agents and uses thereof
|
|
JP7383620B2
(ja)
|
2018-01-31 |
2023-11-20 |
セルジーン コーポレイション |
養子細胞療法およびチェックポイント阻害剤を使用する併用療法
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
CN111801331A
(zh)
|
2018-02-28 |
2020-10-20 |
诺华股份有限公司 |
吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
|
|
JP2021517589A
(ja)
|
2018-03-12 |
2021-07-26 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3768698B1
(en)
|
2018-03-19 |
2025-02-12 |
MultiVir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
|
AU2019246043B2
(en)
|
2018-03-25 |
2024-07-04 |
Snipr Biome Aps. |
Treating and preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
SG11202009498RA
(en)
|
2018-03-27 |
2020-10-29 |
Univ Texas |
Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
|
|
CN111989095A
(zh)
|
2018-04-16 |
2020-11-24 |
上海岸阔医药科技有限公司 |
预防或治疗肿瘤疗法副作用的方法
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
AU2019264232A1
(en)
|
2018-05-04 |
2020-11-12 |
Tollys |
TLR3 ligands that activate both epithelial and myeloid cells
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
|
EP3810109B1
(en)
|
2018-05-31 |
2024-08-07 |
Peloton Therapeutics, Inc. |
Compounds and compositions for inhibiting cd73
|
|
EP3801617A1
(en)
|
2018-06-01 |
2021-04-14 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
|
EP3802599B1
(en)
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
US20210230289A1
(en)
|
2018-06-12 |
2021-07-29 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
MX2020012107A
(es)
|
2018-06-18 |
2021-01-29 |
Innate Pharma |
Composiciones y procedimientos para el tratamiento del cancer.
|
|
CN112585166A
(zh)
|
2018-06-23 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
US11359024B2
(en)
|
2018-09-07 |
2022-06-14 |
Pfizer Inc. |
Anti-AVB8 antibodies and compositions and uses thereof
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
AU2019339777B2
(en)
|
2018-09-12 |
2022-09-01 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
|
SG11202103022WA
(en)
|
2018-09-25 |
2021-04-29 |
Harpoon Therapeutics Inc |
Dll3 binding proteins and methods of use
|
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
|
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
JP2022502385A
(ja)
|
2018-09-29 |
2022-01-11 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための化合物の製造方法
|
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
KR102262012B1
(ko)
|
2018-10-15 |
2021-06-09 |
연세대학교 산학협력단 |
생산성이 향상된 항체 및 이의 제조방법
|
|
KR102885113B1
(ko)
|
2018-10-18 |
2025-11-13 |
머크 샤프 앤드 돔 엘엘씨 |
항-rsv 항체의 제제 및 그의 사용 방법
|
|
US20210393799A1
(en)
|
2018-10-29 |
2021-12-23 |
Wisconsin Alumni Research Foundation |
Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy
|
|
US11564995B2
(en)
|
2018-10-29 |
2023-01-31 |
Wisconsin Alumni Research Foundation |
Peptide-nanoparticle conjugates
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
MA54079A
(fr)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
|
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
|
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
WO2020106983A1
(en)
|
2018-11-21 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for treating cancer
|
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
MX2021006393A
(es)
|
2018-11-29 |
2021-10-13 |
Univ Texas |
Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
|
|
PL3886875T3
(pl)
|
2018-11-30 |
2024-09-09 |
Juno Therapeutics, Inc. |
Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
|
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
SG11202104331YA
(en)
|
2018-12-11 |
2021-05-28 |
Theravance Biopharma R&D Ip Llc |
Naphthyridine and quinoline derivatives useful as alk5 inhibitors
|
|
EP3897624A1
(en)
|
2018-12-17 |
2021-10-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sulconazole as a furin inhibitor
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
WO2020127965A1
(en)
|
2018-12-21 |
2020-06-25 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
EP3911670B1
(en)
|
2019-01-15 |
2024-12-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
TWI894135B
(zh)
|
2019-01-25 |
2025-08-21 |
德商百靈佳殷格翰國際股份有限公司 |
編碼ccl21之重組棒狀病毒
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
AU2020221821A1
(en)
|
2019-02-13 |
2021-08-26 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
WO2020191084A1
(en)
|
2019-03-18 |
2020-09-24 |
The Regents Of The University Of California |
Augmentation of t-cell activation by oscillatory forces and engineered antigen-presenting cells
|
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
|
US20220160692A1
(en)
|
2019-04-09 |
2022-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
|
SG11202111106WA
(en)
|
2019-04-23 |
2021-11-29 |
Innate Pharma |
Cd73 blocking antibodies
|
|
US12492380B2
(en)
|
2019-05-09 |
2025-12-09 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
SG11202111262XA
(en)
|
2019-05-13 |
2021-11-29 |
Regeneron Pharma |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
|
JP2022532766A
(ja)
|
2019-05-17 |
2022-07-19 |
キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド |
家族性腺腫性ポリポーシスを処置するための方法
|
|
US20220244263A1
(en)
|
2019-05-28 |
2022-08-04 |
The Regents Of The University Of California |
Methods for treating small cell neuroendocrine and related cancers
|
|
BR112021024438A2
(pt)
|
2019-06-03 |
2022-02-15 |
Univ Chicago |
Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno
|
|
BR112021024402A2
(pt)
|
2019-06-03 |
2022-02-15 |
Univ Chicago |
Métodos e composições para tratamento de câncer com adjuvantes direcionados ao câncer
|
|
US20220349890A1
(en)
*
|
2019-06-18 |
2022-11-03 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
A method for predicting risk of recurrence for early-stage colon cancer by measuring focal adhesion kinase
|
|
MA56533A
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Co |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1
|
|
JP2022536850A
(ja)
|
2019-06-18 |
2022-08-19 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
KR20220061977A
(ko)
|
2019-08-12 |
2022-05-13 |
퓨리노미아 바이오테크, 아이엔씨. |
Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
|
|
WO2021042066A1
(en)
|
2019-08-30 |
2021-03-04 |
Foundation Medicine, Inc. |
Kmt2a-maml2 fusion molecules and uses thereof
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
CN114786776B
(zh)
|
2019-09-18 |
2026-03-24 |
拉姆卡普生物阿尔法股份公司 |
针对ceacam5和cd3的双特异性抗体
|
|
MX2022003192A
(es)
|
2019-09-18 |
2022-04-11 |
Novartis Ag |
Proteinas de fusion nkg2d y sus usos.
|
|
AU2020353055B2
(en)
|
2019-09-26 |
2024-03-07 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
EP4058593A4
(en)
|
2019-11-12 |
2023-11-15 |
Foundation Medicine, Inc. |
METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
|
|
CN114728941A
(zh)
|
2019-11-22 |
2022-07-08 |
施万生物制药研发Ip有限责任公司 |
作为alk5抑制剂的经取代的1,5-萘啶或喹啉
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
AU2020397956A1
(en)
|
2019-12-04 |
2022-07-07 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021141977A1
(en)
|
2020-01-07 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
KR20220132598A
(ko)
|
2020-01-28 |
2022-09-30 |
제넨테크, 인크. |
암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
|
|
KR20220133238A
(ko)
|
2020-01-29 |
2022-10-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
|
|
US20230112470A1
(en)
|
2020-01-29 |
2023-04-13 |
Board Of Regents, The University Of Texas System |
Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
IL295896A
(en)
|
2020-02-26 |
2022-10-01 |
Biograph 55 Inc |
c19 c38 bispecific antibodies
|
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
|
|
WO2021176330A1
(en)
|
2020-03-03 |
2021-09-10 |
Array Biopharma Inc. |
Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
|
|
CA3172423A1
(en)
|
2020-03-20 |
2021-03-22 |
Alex WESSELHOEFT |
Circular rna compositions and methods
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
|
WO2021239838A2
(en)
|
2020-05-26 |
2021-12-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
|
BR112022023753A2
(pt)
|
2020-06-03 |
2022-12-20 |
Boehringer Ingelheim Int |
Rhabdovírus recombinante que codifica para uma proteína de fusão fc de domínio extracelular cd80
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
CN116323607A
(zh)
|
2020-06-10 |
2023-06-23 |
施万生物制药研发Ip有限责任公司 |
用作alk5抑制剂的萘啶衍生物
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP2023540217A
(ja)
|
2020-08-26 |
2023-09-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｄ－１阻害剤を投与することによりがんを処置する方法
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
JP2023542297A
(ja)
|
2020-09-14 |
2023-10-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
異種プライムブーストワクチン
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
IL300024A
(en)
|
2020-10-20 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
|
|
CA3195572A1
(en)
|
2020-11-04 |
2022-05-12 |
Heidelberg Pharma Research Gmbh |
Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
|
|
JP2023548556A
(ja)
|
2020-11-05 |
2023-11-17 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
|
|
CA3200878A1
(en)
|
2020-11-12 |
2022-05-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
EP4259149A1
(en)
|
2020-12-08 |
2023-10-18 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
|
ES2967381T3
(es)
|
2020-12-18 |
2024-04-30 |
Lamkap Bio Beta Ag |
Anticuerpos biespecíficos contra CEACAM5 y CD47
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
JP2024503480A
(ja)
|
2021-01-19 |
2024-01-25 |
ウィリアム マーシュ ライス ユニバーシティ |
ポリペプチドの骨特異的送達法
|
|
AU2022211682A1
(en)
|
2021-01-22 |
2023-08-03 |
Mendus B.V. |
Methods of tumor vaccination
|
|
AU2022212123A1
(en)
|
2021-01-29 |
2023-09-07 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
WO2022171121A1
(zh)
|
2021-02-10 |
2022-08-18 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
JP2024508304A
(ja)
*
|
2021-03-02 |
2024-02-26 |
ノヴァロック バイオセラピューティクス， リミテッド |
Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用
|
|
WO2022184937A1
(en)
|
2021-03-05 |
2022-09-09 |
Leadartis, S.L. |
Trimeric polypeptides and uses thereof in the treatment of cancer
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN117241832A
(zh)
|
2021-03-19 |
2023-12-15 |
海德堡医药研究有限责任公司 |
B淋巴细胞特异性的鹅膏毒素抗体缀合物
|
|
EP4313123A1
(en)
|
2021-03-23 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
US12016860B2
(en)
|
2021-04-08 |
2024-06-25 |
Nurix Therapeutics, Inc. |
Combination therapies with Cbl-b inhibitor compounds
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
AU2022253474A1
(en)
|
2021-04-08 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
KR20230167097A
(ko)
|
2021-04-09 |
2023-12-07 |
제넨테크, 인크. |
Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US20250282871A1
(en)
|
2021-05-21 |
2025-09-11 |
Tianjin Lipogen Technology Co., Ltd |
Pharmaceutical combination and use thereof
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
|
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
JP2024525758A
(ja)
|
2021-07-13 |
2024-07-12 |
ビオンテック・ソシエタス・エウロパエア |
がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
|
|
WO2023015198A1
(en)
|
2021-08-04 |
2023-02-09 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
|
|
US20250114452A1
(en)
|
2021-08-04 |
2025-04-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
CA3231180A1
(en)
|
2021-09-08 |
2023-03-16 |
Redona Therapeutics, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
|
JP2024536133A
(ja)
|
2021-09-29 |
2024-10-04 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
抗ｈｓｐ７０抗体およびその治療的使用
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
CN118369419A
(zh)
|
2021-10-05 |
2024-07-19 |
赛托维亚治疗有限责任公司 |
自然杀伤细胞及其使用方法
|
|
US20250002600A1
(en)
|
2021-10-06 |
2025-01-02 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination therapy
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
KR20240099161A
(ko)
|
2021-10-20 |
2024-06-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
Bcma를 표적화하는 조성물 및 이의 사용 방법
|
|
US20240409934A1
(en)
|
2021-10-25 |
2024-12-12 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
KR20240103030A
(ko)
|
2021-11-17 |
2024-07-03 |
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 |
범용 사르베코바이러스 백신
|
|
JP2025500922A
(ja)
|
2021-12-16 |
2025-01-15 |
ヴァレリオ・セラピューティクス |
新規のコンジュゲートされた核酸分子及びその使用
|
|
WO2023129438A1
(en)
|
2021-12-28 |
2023-07-06 |
Wisconsin Alumni Research Foundation |
Hydrogel compositions for use for depletion of tumor associated macrophages
|
|
WO2023142996A1
(zh)
|
2022-01-28 |
2023-08-03 |
上海岸阔医药科技有限公司 |
预防或治疗与抗肿瘤剂相关的疾病或病症的方法
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
EP4479388A1
(en)
|
2022-02-14 |
2024-12-25 |
Gilead Sciences, Inc. |
Antiviral naphthyridinone compounds
|
|
US20250152643A1
(en)
|
2022-02-17 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
|
|
WO2023155905A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海岸阔医药科技有限公司 |
化合物及其用途
|
|
EP4514382A1
(en)
|
2022-04-28 |
2025-03-05 |
Musc Foundation for Research Development |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到ｃｄ２７之結合劑
|
|
US20250230256A1
(en)
|
2022-06-16 |
2025-07-17 |
Lamkap Bio Beta Ltd |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
CA3263560A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
US20240165257A1
(en)
|
2022-11-01 |
2024-05-23 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
|
JP2025541738A
(ja)
|
2022-12-01 |
2025-12-23 |
ビオンテック・ソシエタス・エウロパエア |
抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
CR20250279A
(es)
|
2023-01-20 |
2025-08-25 |
Boehringer Ingelheim Int |
Proteínas de fusión fc de il-12
|
|
JP2026505276A
(ja)
|
2023-01-31 |
2026-02-13 |
ユニバーシティ オブ ロチェスター |
Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ感染症を治療するための免疫チェックポイント遮断療法
|
|
WO2024192033A1
(en)
|
2023-03-13 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
|
CN120936385A
(zh)
|
2023-03-13 |
2025-11-11 |
海德堡医药研究有限责任公司 |
用于在癌症治疗中使用的皮下施用的抗体-药物缀合物
|
|
JP2026510999A
(ja)
|
2023-03-21 |
2026-04-10 |
バイオグラフ ５５，インク． |
Ｃｄ１９／ｃｄ３８多重特異性抗体
|
|
CN121620391A
(zh)
|
2023-04-06 |
2026-03-06 |
金麦安博股份有限公司 |
用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
CN121285385A
(zh)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
能够与ox40结合的抗体、其变体及其用途
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
US20250114468A1
(en)
|
2023-10-09 |
2025-04-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
|
|
WO2025106736A2
(en)
|
2023-11-15 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025132695A1
(en)
|
2023-12-19 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Recombinant rhabdovirus encoding for a gasdermin
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025248505A1
(en)
|
2024-05-31 |
2025-12-04 |
Wayne State University |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026012976A1
(en)
|
2024-07-08 |
2026-01-15 |
Institut National de la Santé et de la Recherche Médicale |
Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
|
|
WO2026037839A2
(en)
|
2024-08-12 |
2026-02-19 |
ONA Therapeutics S.L. |
Anti-fgfr4 molecules and uses thereof
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
WO2026052851A2
(en)
|
2024-09-09 |
2026-03-12 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
|